Review Article

妇科代谢物生物标记:正确之路还是错误之路?

卷 27, 期 22, 2020

页: [3611 - 3622] 页: 12

弟呕挨: 10.2174/0929867326666190104124245

价格: $65

摘要

染色体技术(基因组学、转录组学、蛋白质组学和代谢组学)在当今医学中越来越重要。其中,代谢组学最准确地反映了人体功能的微小变化,因为它关注的是代谢组,即代谢产物的中间和末端。因此,代谢组学积极参与基础和临床研究,寻找潜在的生物标记物。该生物标记物可用于患者的诊断、治疗、分层以及预后。妇科就是一个很好的例子,因为许多妇科疾病缺乏有效的生物标记物。在本文中,我们旨在总结研究结果,致力于寻找最常见妇科疾病的潜在代谢生物标记物。

关键词: 代谢组学,生物标记物,妇科,宫颈癌,卵巢肿瘤,子宫内膜异位,多囊卵巢综合征。

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Arbyn, M.; Anttila, A.; Jordan, J.; Ronco, G.; Schenck, U.; Segnan, N.; Wiener, H.; Herbert, A.; von Karsa, L. European guidelines for quality assurance in cervical cancer screening . Second edition--summary document Ann. Oncol.,; , 2010. 21(3), 448-458
[http://dx.doi.org/10.1093/annonc/mdp471] [PMID: 20176693]
[3]
Yin, M.Z.; Tan, S.; Li, X.; Hou, Y.; Cao, G.; Li, K.; Kou, J.; Lou, G. Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study. Tumour Biol., 2016, 37(4), 5485-5492.
[http://dx.doi.org/10.1007/s13277-015-4164-x] [PMID: 26566624]
[4]
Yang, K.; Xia, B.; Wang, W.; Cheng, J.; Yin, M.; Xie, H.; Li, J.; Ma, L.; Yang, C.; Li, A.; Fan, X.; Dhillon, H.S.; Hou, Y.; Lou, G.; Li, K. A comprehensive analysis of metabolomics and transcriptomics in cervical cancer. Sci. Rep., 2017, 7, 43353.
[http://dx.doi.org/10.1038/srep43353] [PMID: 28225065]
[5]
Ye, N.; Liu, C.; Shi, P. Metabolomics analysis of cervical cancer, cervical intraepithelial neoplasia and chronic cervicitis by 1H NMR spectroscopy. Eur. J. Gynaecol. Oncol., 2015, 36(2), 174-180.
[PMID: 26050356]
[6]
Hasim, A.; Ali, M.; Mamtimin, B.; Ma, J.Q.; Li, Q.Z.; Abudula, A. Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by (1)H NMR spectroscopy. Exp. Ther. Med., 2012, 3(6), 945-951.
[http://dx.doi.org/10.3892/etm.2012.509] [PMID: 22969997]
[7]
Muñoz, N.; Hernandez-Suarez, G.; Méndez, F.; Molano, M.; Posso, H.; Moreno, V.; Murillo, R.; Ronderos, M.; Meijer, C.; Muñoz, A. Instituto Nacional de Cancerología HPV Study Group. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br. J. Cancer, 2009, 100(7), 1184-1190.
[http://dx.doi.org/10.1038/sj.bjc.6604972] [PMID: 19293802]
[8]
Walker, H.; Burrell, M.; Flatley, J.; Powers, H. A metabolite profiling method for diagnosis of precancerous cervical lesions and HPV persistence. Bioanalysis, 2017, 9(8), 601-608.
[http://dx.doi.org/10.4155/bio-2017-0012] [PMID: 28508693]
[9]
Hou, Y.; Yin, M.; Sun, F.; Zhang, T.; Zhou, X.; Li, H.; Zheng, J.; Chen, X.; Li, C.; Ning, X.; Lou, G.; Li, K. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. Mol. Biosyst., 2014, 10(8), 2126-2133.
[http://dx.doi.org/10.1039/C4MB00054D] [PMID: 24865370]
[10]
Chai, Y.; Wang, J.; Wang, T.; Yang, Y.; Su, J.; Shi, F.; Wang, J.; Zhou, X.; He, B.; Ma, H.; Liu, Z. Application of 1H NMR spectroscopy-based metabonomics to feces of cervical cancer patients with radiation-induced acute intestinal symptoms. Radiother. Oncol., 2015, 117(2), 294-301.
[http://dx.doi.org/10.1016/j.radonc.2015.07.037] [PMID: 26277430]
[11]
Liang, Q.; Yu, Q.; Wu, H.; Zhu, Y-Z.; Zhang, A-H. Metabolite fingerprint analysis of cervical cancer using LC-QTOF/MS and multivariate data analysis. Anal. Methods, 2014, 6(12), 3937-3942.
[http://dx.doi.org/10.1039/C4AY00399C]
[12]
Fan, L.; Zhang, W.; Yin, M.; Zhang, T.; Wu, X.; Zhang, H.; Sun, M.; Li, Z.; Hou, Y.; Zhou, X.; Lou, G.; Li, K. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol., 2012, 51(4), 473-479.
[http://dx.doi.org/10.3109/0284186X.2011.648338] [PMID: 22283470]
[13]
Lee, J.H.; Kim, Y.H.; Kim, K-H.; Cho, J.Y.; Woo, S.M.; Yoo, B.C.; Kim, S.C. Profiling of serum metabolites using MALDI-TOF and Triple-TOF mass spectrometry to develop a screen for ovarian cancer. Cancer Res. Treat., 2018, 50(3), 883-893.
[http://dx.doi.org/10.4143/crt.2017.275] [PMID: 28934848]
[14]
Slupsky, C.M.; Steed, H.; Wells, T.H.; Dabbs, K.; Schepansky, A.; Capstick, V.; Faught, W.; Sawyer, M.B. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res., 2010, 16(23), 5835-5841.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-1434] [PMID: 20956617]
[15]
Zhang, T.; Wu, X.; Ke, C.; Yin, M.; Li, Z.; Fan, L.; Zhang, W.; Zhang, H.; Zhao, F.; Zhou, X.; Lou, G.; Li, K. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J. Proteome Res., 2013, 12(1), 505-512.
[http://dx.doi.org/10.1021/pr3009572] [PMID: 23163809]
[16]
Corrado, G.; Salutari, V.; Palluzzi, E.; Distefano, M.G.; Scambia, G.; Ferrandina, G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev. Anticancer Ther., 2017, 17(12), 1147-1158.
[http://dx.doi.org/10.1080/14737140.2017.1398088] [PMID: 29086618]
[17]
Turkoglu, O.; Zeb, A.; Graham, S.; Szyperski, T.; Szender, J.B.; Odunsi, K.; Bahado-Singh, R. Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. Metabolomics, 2016, 12(4), 60.
[http://dx.doi.org/10.1007/s11306-016-0990-0] [PMID: 28819352]
[18]
Fan, L.; Yin, M.; Ke, C.; Ge, T.; Zhang, G.; Zhang, W.; Zhou, X.; Lou, G.; Li, K. Use of plasma metabolomics to identify diagnostic biomarkers for early stage epithelial ovarian cancer. J. Cancer, 2016, 7(10), 1265-1272.
[http://dx.doi.org/10.7150/jca.15074] [PMID: 27390602]
[19]
Xie, H.; Hou, Y.; Cheng, J.; Openkova, M.S.; Xia, B.; Wang, W.; Li, A.; Yang, K.; Li, J.; Xu, H.; Yang, C.; Ma, L.; Li, Z.; Fan, X.; Li, K.; Lou, G. Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer. Oncotarget, 2017, 8(19), 32134-32146.
[http://dx.doi.org/10.18632/oncotarget.16739] [PMID: 28389631]
[20]
Zhang, H.; Ge, T.; Cui, X.; Hou, Y.; Ke, C.; Yang, M.; Yang, K.; Wang, J.; Guo, B.; Zhang, F.; Lou, G.; Li, K. Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling. Mol. Biosyst., 2015, 11(2), 516-521.
[http://dx.doi.org/10.1039/C4MB00407H] [PMID: 25424060]
[21]
Garcia, E.; Andrews, C.; Hua, J.; Kim, H.L.; Sukumaran, D.K.; Szyperski, T.; Odunsi, K. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J. Proteome Res., 2011, 10(4), 1765-1771.
[http://dx.doi.org/10.1021/pr101050d] [PMID: 21218854]
[22]
Hilvo, M.; de Santiago, I.; Gopalacharyulu, P.; Schmitt, W.D.; Budczies, J.; Kuhberg, M.; Dietel, M.; Aittokallio, T.; Markowetz, F.; Denkert, C.; Sehouli, J.; Frezza, C.; Darb-Esfahani, S.; Braicu, E.I. Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas. Cancer Res., 2016, 76(4), 796-804.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2298] [PMID: 26685161]
[23]
Ke, C.; Hou, Y.; Zhang, H.; Fan, L.; Ge, T.; Guo, B.; Zhang, F.; Yang, K.; Wang, J.; Lou, G.; Li, K. Large-scale profiling of metabolic dysregulation in ovarian cancer. Int. J. Cancer, 2015, 136(3), 516-526.
[http://dx.doi.org/10.1002/ijc.29010] [PMID: 24895217]
[24]
Selen, E.S.; Bolandnazar, Z.; Tonelli, M.; Bütz, D.E.; Haviland, J.A.; Porter, W.P.; Assadi-Porter, F.M. Assadi-Porter, F.M. NMR metabolomics show evidence for mitochondrial oxidative stress in a mouse model of polycystic ovary syndrome. J. Proteome Res., 2015, 14(8), 3284-3291.
[http://dx.doi.org/10.1021/acs.jproteome.5b00307] [PMID: 26076986]
[25]
Tata, B.; Mimouni, N.E.H.; Barbotin, A-L.; Malone, S.A.; Loyens, A.; Pigny, P.; Dewailly, D.; Catteau-Jonard, S.; Sundström-Poromaa, I.; Piltonen, T.T.; Dal Bello, F.; Medana, C.; Prevot, V.; Clasadonte, J.; Giacobini, P. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat. Med., 2018, 24(6), 834-846.
[http://dx.doi.org/10.1038/s41591-018-0035-5] [PMID: 29760445]
[26]
Balaban, B.; Urman, B. Effect of oocyte morphology on embryo development and implantation. Reprod. Biomed. Online, 2006, 12(5), 608-615.
[http://dx.doi.org/10.1016/S1472-6483(10)61187-X] [PMID: 16790106]
[27]
Arya, B.K.; Haq, A.U.; Chaudhury, K. Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Med. Hypotheses, 2012, 78(4), 475-478.
[http://dx.doi.org/10.1016/j.mehy.2012.01.009] [PMID: 22336088]
[28]
Galazis, N.; Iacovou, C.; Haoula, Z.; Atiomo, W. Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol., 2012, 160(2), 121-130.
[http://dx.doi.org/10.1016/j.ejogrb.2011.11.005] [PMID: 22136882]
[29]
Zhao, Y.; Fu, L.; Li, R.; Wang, L.N.; Yang, Y.; Liu, N.N.; Zhang, C.M.; Wang, Y.; Liu, P.; Tu, B.B.; Zhang, X.; Qiao, J. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med., 2012, 10, 153.
[http://dx.doi.org/10.1186/1741-7015-10-153] [PMID: 23198915]
[30]
Sun, L.; Hu, W.; Liu, Q.; Hao, Q.; Sun, B.; Zhang, Q.; Mao, S.; Qiao, J.; Yan, X. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J. Proteome Res., 2012, 11(5), 2937-2946.
[http://dx.doi.org/10.1021/pr3000317] [PMID: 22428626]
[31]
Atiomo, W.; Daykin, C.A. Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study. Mol. Hum. Reprod., 2012, 18(11), 546-553.
[http://dx.doi.org/10.1093/molehr/gas029] [PMID: 22809877]
[32]
Zhao, X.; Xu, F.; Qi, B.; Hao, S.; Li, Y.; Li, Y.; Zou, L.; Lu, C.; Xu, G.; Hou, L. Serum metabolomics study of polycystic ovary syndrome based on liquid chromatography-mass spectrometry. J. Proteome Res., 2014, 13(2), 1101-1111.
[http://dx.doi.org/10.1021/pr401130w] [PMID: 24428203]
[33]
Dong, F.; Deng, D.; Chen, H.; Cheng, W.; Li, Q.; Luo, R.; Ding, S. Serum metabolomics study of polycystic ovary syndrome based on UPLC-QTOF-MS coupled with a pattern recognition approach. Anal. Bioanal. Chem., 2015, 407(16), 4683-4695.
[http://dx.doi.org/10.1007/s00216-015-8670-x] [PMID: 25860656]
[34]
Wang, W.; Wang, S.; Tan, S.; Wen, M.; Qian, Y.; Zeng, X.; Guo, Y.; Yu, C. Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS. Clin. Chim. Acta, 2015, 448, 39-47.
[http://dx.doi.org/10.1016/j.cca.2015.06.008] [PMID: 26093338]
[35]
Chen, Y.X.; Zhang, X.J.; Huang, J.; Zhou, S.J.; Liu, F.; Jiang, L.L.; Chen, M.; Wan, J.B.; Yang, D.Z. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. J. Pharm. Biomed. Anal., 2016, 121, 141-150.
[http://dx.doi.org/10.1016/j.jpba.2016.01.025] [PMID: 26808063]
[36]
RoyChoudhury, S.; Mishra, B.P.; Khan, T.; Chattopadhayay, R.; Lodh, I.; Datta Ray, C.; Bose, G.; Sarkar, H.S.; Srivastava, S.; Joshi, M.V.; Chakravarty, B.; Chaudhury, K. Serum metabolomics of Indian women with polycystic ovary syndrome using 1H NMR coupled with a pattern recognition approach. Mol. Biosyst., 2016, 12(11), 3407-3416.
[http://dx.doi.org/10.1039/C6MB00420B] [PMID: 27714060]
[37]
Chang, A.Y.; Lalia, A.Z.; Jenkins, G.D.; Dutta, T.; Carter, R.E.; Singh, R.J.; Nair, K.S. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome. Metabolism, 2017, 71, 52-63.
[http://dx.doi.org/10.1016/j.metabol.2017.03.002] [PMID: 28521878]
[38]
Szczuko, M.; Zapałowska-Chwyć, M.; Drozd, A.; Maciejewska, D.; Starczewski, A.; Stachowska, E. Metabolic pathways of oleic and palmitic acid are intensified in PCOS patients with normal androgen levels. Prostaglandins Leukot. Essent. Fatty Acids, 2017, 126, 105-111.
[http://dx.doi.org/10.1016/j.plefa.2017.09.001] [PMID: 29031387]
[39]
RoyChoudhury. S.; More, T.H.; Chattopadhyay, R Lodh, I.; Ray, C.D.; Bose, G.; Sarkar, H.S.; Chakravarty, B.; Rapole, S.; Chaudhury, K. Polycystic ovary syndrome in Indian women: a mass spectrometry based serum metabolomics approach. Metabolomics, 2017, 13(10), 115.
[http://dx.doi.org/10.1007/s11306-017-1253-4]
[40]
Insenser, M.; Montes-Nieto, R.; Murri, M.; Escobar-Morreale, H.F. Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. Mol. Cell. Endocrinol., 2013, 370(1-2), 65-77.
[http://dx.doi.org/10.1016/j.mce.2013.02.009] [PMID: 23422073]
[41]
Murri, M.; Insenser, M.; Escobar-Morreale, H.F. Metabolomics in polycystic ovary syndrome. Clin. Chim. Acta, 2014, 429, 181-188.
[http://dx.doi.org/10.1016/j.cca.2013.12.018] [PMID: 24368231]
[42]
Medicine, P.C.A.S.R. Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil. Steril., 2012, 98(3), 591-598.
[http://dx.doi.org/10.1016/j.fertnstert.2012.05.031] [PMID: 22704630]
[43]
Meuleman, C.; Vandenabeele, B.; Fieuws, S.; Spiessens, C.; Timmerman, D.; D’Hooghe, T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil. Steril., 2009, 92(1), 68-74.
[http://dx.doi.org/10.1016/j.fertnstert.2008.04.056] [PMID: 18684448]
[44]
Scutiero, G.; Iannone, P.; Bernardi, G.; Bonaccorsi, G.; Spadaro, S.; Volta, C.A.; Greco, P.; Nappi, L. Oxidative stress and endometriosis: a systematic review of the literature. Oxid. Med. Cell. Longev., 2017, 2017 7265238
[http://dx.doi.org/10.1155/2017/7265238] [PMID: 29057034]
[45]
Vouk, K.; Hevir, N.; Ribić-Pucelj, M.; Haarpaintner, G.; Scherb, H.; Osredkar, J.; Möller, G.; Prehn, C.; Rižner, T.L.; Adamski, J. Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Hum. Reprod., 2012, 27(10), 2955-2965.
[http://dx.doi.org/10.1093/humrep/des152] [PMID: 22859507]
[46]
Yang, H.; Lau, W.B.; Lau, B.; Xuan, Y.; Zhou, S.; Zhao, L.; Luo, Z.; Lin, Q.; Ren, N.; Zhao, X.; Wei, Y. A mass spectrometric insight into the origins of benign gynecological disorders. Mass Spectrom. Rev., 2017, 36(3), 450-470.
[http://dx.doi.org/10.1002/mas.21484] [PMID: 26633258]
[47]
Somigliana, E.; Vercellini, P.; Vigano’, P.; Benaglia, L.; Crosignani, P.G.; Fedele, L. Non-invasive diagnosis of endometriosis: the goal or own goal? Hum. Reprod., 2010, 25(8), 1863-1868.
[http://dx.doi.org/10.1093/humrep/deq141] [PMID: 20519246]
[48]
Mol, B.W.; Bayram, N.; Lijmer, J.G.; Wiegerinck, M.A.; Bongers, M.Y.; van der Veen, F.; Bossuyt, P.M. The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis. Fertil. Steril., 1998, 70(6), 1101-1108.
[http://dx.doi.org/10.1016/S0015-0282(98)00355-0] [PMID: 9848302]
[49]
McLeod, B.S.; Retzloff, M.G. Epidemiology of endometriosis: an assessment of risk factors. Clin. Obstet. Gynecol., 2010, 53(2), 389-396.
[http://dx.doi.org/10.1097/GRF.0b013e3181db7bde] [PMID: 20436315]
[50]
Draj, H.A.; Abbas, A.A.; Abdullah, T.H. Serum levels of glycodelin a and soluble intracellular adhesion molecule-1 as biomarkers for endometriosis. Iraqi JMS, 2017, 15(4), 345-349.
[51]
Ekarattanawong, S.; Tanprasertkul, C.; Somprasit, C.; Chamod, P.; Tiengtip, R.; Bhamarapravatana, K.; Suwannarurk, K. Possibility of using superoxide dismutase and glutathione peroxidase as endometriosis biomarkers. Int. J. Womens Health, 2017, 9, 711-716.
[http://dx.doi.org/10.2147/IJWH.S141021] [PMID: 29026339]
[52]
Reis, F.M.; Monteiro, C.S.; Carneiro, M.M. Biomarkers of pelvic endometriosis. Rev. Bras. Ginecol. Obstet., 2017, 39(3), 91-93.
[http://dx.doi.org/10.1055/s-0037-1601398] [PMID: 28359109]
[53]
Trapero, C.; Jover, L.; Fernández-Montolí, M.E.; García-Tejedor, A.; Vidal, A.; Gómez de Aranda, I.; Ponce, J.; Matias-Guiu, X.; Martín-Satué, M. Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis. Am. J. Reprod. Immunol., 2018, 79(2)
[http://dx.doi.org/10.1111/aji.12794] [PMID: 29194839]
[54]
Dutta, M.; Joshi, M.; Srivastava, S.; Lodh, I.; Chakravarty, B.; Chaudhury, K. A metabonomics approach as a means for identification of potential biomarkers for early diagnosis of endometriosis. Mol. Biosyst., 2012, 8(12), 3281-3287.
[http://dx.doi.org/10.1039/c2mb25353d] [PMID: 23079773]
[55]
Vissers, Y.L.; Dejong, C.H.; Luiking, Y.C.; Fearon, K.C.; von Meyenfeldt, M.F.; Deutz, N.E. Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am. J. Clin. Nutr., 2005, 81(5), 1142-1146.
[http://dx.doi.org/10.1093/ajcn/81.5.1142] [PMID: 15883440]
[56]
Vodolazkaia, A.; El-Aalamat, Y.; Popovic, D.; Mihalyi, A.; Bossuyt, X.; Kyama, C.M.; Fassbender, A.; Bokor, A.; Schols, D.; Huskens, D.; Meuleman, C.; Peeraer, K.; Tomassetti, C.; Gevaert, O.; Waelkens, E.; Kasran, A.; De Moor, B.; D’Hooghe, T.M. Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. Hum. Reprod., 2012, 27(9), 2698-2711.
[http://dx.doi.org/10.1093/humrep/des234] [PMID: 22736326]
[57]
Ghazi, N.; Arjmand, M.; Akbari, Z.; Mellati, A.O.; Saheb-Kashaf, H.; Zamani, Z. (1)H NMR- based metabolomics approaches as non- invasive tools for diagnosis of endometriosis. Int. J. Reprod. Biomed. (Yazd), 2016, 14(1), 1-8.
[http://dx.doi.org/10.29252/ijrm.14.1.1] [PMID: 27141542]
[58]
Jadoul, P.; Kitajima, M.; Donnez, O.; Squifflet, J.; Donnez, J. Surgical treatment of ovarian endometriomas: state of the art? Fertil. Steril., 2012, 98(3), 556-563.
[http://dx.doi.org/10.1016/j.fertnstert.2012.06.023] [PMID: 22763094]
[59]
Kouremenos, K.A.; Johansson, M.; Marriott, P.J. Advances in gas chromatographic methods for the identification of biomarkers in cancer. J. Cancer, 2012, 3, 404-420.
[http://dx.doi.org/10.7150/jca.4956] [PMID: 23074381]
[60]
Spratlin, J.L.; Serkova, N.J.; Eckhardt, S.G. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res., 2009, 15(2), 431-440.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1059] [PMID: 19147747]
[61]
Cuvillier, O. Sphingosine in apoptosis signaling. Biochim. Biophys. Acta, 2002, 1585(2-3), 153-162.
[http://dx.doi.org/10.1016/S1388-1981(02)00336-0] [PMID: 12531549]
[62]
Sano, M.; Morishita, T.; Nozaki, M.; Yokoyama, M.; Watanabe, Y.; Nakano, H. Elevation of the phospholipase A2 activity in peritoneal fluid cells from women with endometriosis. Fertil. Steril., 1994, 61(4), 657-662.
[http://dx.doi.org/10.1016/S0015-0282(16)56642-4] [PMID: 8150107]
[63]
Vouk, K.; Ribič-Pucelj, M.; Adamski, J.; Rižner, T.L. Altered levels of acylcarnitines, phosphatidylcholines, and sphingomyelins in peritoneal fluid from ovarian endometriosis patients. J. Steroid Biochem. Mol. Biol., 2016, 159, 60-69.
[http://dx.doi.org/10.1016/j.jsbmb.2016.02.023] [PMID: 26921767]
[64]
Letsiou, S.; Peterse, D.P.; Fassbender, A.; Hendriks, M.M.; van den Broek, N.J.; Berger, R.; O, D.F.; Vanhie, A.; Vodolazkaia, A.; Van Langendonckt, A.; Donnez, J.; Harms, A.C.; Vreeken, R.J.; Groothuis, P.G.; Dolmans, M.M.; Brenkman, A.B.; D’Hooghe, T.M. Endometriosis is associated with aberrant metabolite profiles in plasma. Fertil. Steril., 2017, 107(3), 699-706.e6.
[http://dx.doi.org/10.1016/j.fertnstert.2016.12.032] [PMID: 28259259]
[65]
Melo, A.S.; Rosa-e-Silva, J.C.; Rosa-e-Silva, A.C.; Poli-Neto, O.B.; Ferriani, R.A.; Vieira, C.S. Unfavorable lipid profile in women with endometriosis. Fertil. Steril., 2010, 93(7), 2433-2436.
[http://dx.doi.org/10.1016/j.fertnstert.2009.08.043] [PMID: 19969295]
[66]
Marianna, S.; Alessia, P.; Susan, C.; Francesca, C.; Angela, S.; Francesca, C.; Antonella, N.; Patrizia, I.; Nicola, C.; Emilio, C. Metabolomic profiling and biochemical evaluation of the follicular fluid of endometriosis patients. Mol. Biosyst., 2017, 13(6), 1213-1222.
[http://dx.doi.org/10.1039/C7MB00181A] [PMID: 28475193]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy